首页> 美国卫生研究院文献>Critical Care >Clinical review: Practical recommendations on the management of perioperative heart failure in cardiac surgery
【2h】

Clinical review: Practical recommendations on the management of perioperative heart failure in cardiac surgery

机译:临床评论:心脏手术中围手术期心力衰竭管理的实用建议

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Acute cardiovascular dysfunction occurs perioperatively in more than 20% of cardiosurgical patients, yet current acute heart failure (HF) classification is not applicable to this period. Indicators of major perioperative risk include unstable coronary syndromes, decompensated HF, significant arrhythmias and valvular disease. Clinical risk factors include history of heart disease, compensated HF, cerebrovascular disease, presence of diabetes mellitus, renal insufficiency and high-risk surgery. EuroSCORE reliably predicts perioperative cardiovascular alteration in patients aged less than 80 years. Preoperative B-type natriuretic peptide level is an additional risk stratification factor. Aggressively preserving heart function during cardiosurgery is a major goal. Volatile anaesthetics and levosimendan seem to be promising cardioprotective agents, but large trials are still needed to assess the best cardioprotective agent(s) and optimal protocol(s). The aim of monitoring is early detection and assessment of mechanisms of perioperative cardiovascular dysfunction. Ideally, volume status should be assessed by 'dynamic' measurement of haemodynamic parameters. Assess heart function first by echocardiography, then using a pulmonary artery catheter (especially in right heart dysfunction). If volaemia and heart function are in the normal range, cardiovascular dysfunction is very likely related to vascular dysfunction. In treating myocardial dysfunction, consider the following options, either alone or in combination: low-to-moderate doses of dobutamine and epinephrine, milrinone or levosimendan. In vasoplegia-induced hypotension, use norepinephrine to maintain adequate perfusion pressure. Exclude hypovolaemia in patients under vasopressors, through repeated volume assessments. Optimal perioperative use of inotropes/vasopressors in cardiosurgery remains controversial, and further large multinational studies are needed. Cardiosurgical perioperative classification of cardiac impairment should be based on time of occurrence (precardiotomy, failure to wean, postcardiotomy) and haemodynamic severity of the patient's condition (crash and burn, deteriorating fast, stable but inotrope dependent). In heart dysfunction with suspected coronary hypoperfusion, an intra-aortic balloon pump is highly recommended. A ventricular assist device should be considered before end organ dysfunction becomes evident. Extra-corporeal membrane oxygenation is an elegant solution as a bridge to recovery and/or decision making. This paper offers practical recommendations for management of perioperative HF in cardiosurgery based on European experts' opinion. It also emphasizes the need for large surveys and studies to assess the optimal way to manage perioperative HF in cardiac surgery.
机译:超过20%的心脏外科手术患者围手术期发生急性心血管功能障碍,但当前的急性心力衰竭(HF)分类不适用于该时期。主要围手术期风险的指标包括不稳定的冠状动脉综合征,失代偿性心律失常,严重的心律不齐和瓣膜疾病。临床风险因素包括心脏病史,代偿性心力衰竭,脑血管疾病,存在糖尿病,肾功能不全和高风险手术。 EuroSCORE可靠地预测了80岁以下患者的围手术期心血管疾病改变。术前B型利钠肽水平是另一个危险分层因素。在心脏外科手术中积极保持心脏功能是一个主要目标。挥发性麻醉药和左西孟旦似乎是有前途的心脏保护剂,但仍需要进行大量试验来评估最佳的心脏保护剂和最佳方案。监测的目的是早期发现和评估围手术期心血管功能障碍的机制。理想情况下,应通过血液动力学参数的“动态”测量来评估体积状态。首先通过超声心动图评估心脏功能,然后使用肺动脉导管(尤其是在右心功能不全的情况下)。如果血流量和心脏功能在正常范围内,则心血管功能障碍很可能与血管功能障碍有关。在治疗心肌功能障碍时,请考虑以下选项,可单独使用或组合使用:低至中剂量的多巴酚丁胺和肾上腺素,米力农或左西孟旦。在血管痉挛引起的低血压中,使用去甲肾上腺素维持足够的灌注压力。通过反复进行容量评估,排除血管加压药患者的低血容量。在心脏外科手术中最佳的围术期使用正性肌力药/升压药仍存在争议,因此需要进一步的大型跨国研究。心脏损伤的心脏外科围手术期分类应基于发生时间(心脏切开术,断奶失败,明信片切开术)和患者病情的血流动力学严重程度(崩溃和烧伤,快速恶化,稳定但依赖药物)。对于可疑的冠状动脉灌注不足的心脏功能不全者,强烈建议使用主动脉内球囊泵。在末梢器官功能障碍变得明显之前,应考虑使用心室辅助设备。体外膜氧合是一种优雅的解决方案,可作为恢复和/或决策的桥梁。本文根据欧洲专家的意见,为心脏外科围手术期HF的治疗提供了实用建议。它还强调需要进行大量调查和研究,以评估心脏手术中围手术期HF的最佳治疗方法。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号